Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells.

Cedars-Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States.
Leukemia Research (Impact Factor: 2.69). 08/2006; 30(7):841-8. DOI: 10.1016/j.leukres.2005.12.004
Source: PubMed

ABSTRACT Over many centuries, herbal remedies have treated a variety of ailments. This empiric observational approach has produced a number of leads for formulated medicines. Ganoderma lucidum extract was screened for its anti-proliferative activity using a panel of 26 human cancer cell lines. The six most sensitive hematologic cell lines were: HL-60 (ED50 26 microg/ml), U937 (63 microg/ml), K562 (50 microg/ml), Blin-1 (38 microg/ml), Nalm-6 (30 microg/ml) and RPMI8226 (40 microg/ml). Cell cycle analyses revealed a G2/M arrest, most prominently in HL-60 cells. Four hematopoietic cell lines (HL-60, Blin-1, U937, RPMI8226) were examined for apoptosis, which ranged between 21 and 92%. After exposure to G. lucidum extract, HL-60 cells became multinucleated with an increased DNA content. These results indicate that G. lucidum extract has a profound activity against leukemia, lymphoma and multiple myeloma cells and may be a novel adjunctive therapy for the treatment of hematologic malignancies.

Download full-text


Available from: Takashi Kumagai, Jun 01, 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim of the studyB-cell chronic lymphocytic leukemia (B-CLL) is a neoplasia of the immune system due to an accumulation of clonal B lymphocytes resistant to apoptosis. B-cell abnormal infiltration impairs normal architecture of lymph nodes and other organs of the immune system and therefore the defense against infectious diseases. Single new therapeutic strategies are currently under investigation for triggering specific death of malignant B-CLL cells. Moreover, therapies including combination of several new antitumor agents more effective against tumor processes are being developed.Methods We used an active fraction obtained from Ganoderma lucidum fruiting bodies. This fraction was isolated by methanol extraction and column chromatography on silica gel using butanol:acetic acid:water for elution. This fraction was collected at an Rf of 0.74.ResultsIn this study, we show induction of cytotoxicity, DNA fragmentation and apoptosis on fresh human B-CLL cells by this active fraction from G. lucidum. Different dose-dependent cytotoxic effects were observed depending on the individual immunophenotypes. Even at low concentration, this fraction induced cell death with DNA fragmentation and changes in phosphatidylserine localization in cell membrane on B-cells from CLL patients. It is at low concentration where this active fraction shows a balance between the apoptotic effect and cell viability.Conclusion The high cytotoxic effect observed in peripheral blood mononuclear cells from B-CLL patients as compared with the effect on healthy donors’ cells support its potential antileukemia role in combined therapeutic strategies.
    European Journal of Integrative Medicine 09/2012; 4(3):e335–e343. DOI:10.1016/j.eujim.2012.01.010 · 0.65 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A systematic study of the metabolites in Ganoderma lucidum led to isolation of 43 triterpenoids, six of them (1-6) are hitherto unknown. The structures of the latter were elucidated on the basis of spectroscopic studies and comparison with the known related compounds. All of the compounds were assayed for their inhibitory activities against human HeLa cervical cancer cell lines. Some compounds exhibit significant cytotoxicity, and their structure-activity relationships are discussed.
    Phytochemistry 09/2010; 71(13):1579-85. DOI:10.1016/j.phytochem.2010.06.005 · 3.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ganoderma lucidum (Ling Zhi) is a basidiomycete white rot macrofungus which has been used extensively as "the mushroom of immortality" in China, Japan, Korea and other Asian countries for 2000 years. A great deal of work has been carried out on therapeutic potential of Ganoderma lucidum. The basidiocarp, mycelia and spores of Ganoderma lucidum contain approximately 400 different bioactive compounds, which mainly include triterpenoids, polysaccharides, nucleotides, sterols, steroids, fatty acids, proteins/peptides and trace elements which has been reported to have a number of pharmacological effects including immunomodulation, anti-atherosclerotic, anti-inflammatory, analgesic, chemo-preventive, antitumor, chemo and radio protective, sleep promoting, antibacterial, antiviral (including anti-HIV), hypolipidemic, anti-fibrotic, hepatoprotective, anti-diabetic, anti-androgenic, anti-angiogenic, anti-herpetic, antioxidative and radical-scavenging, anti-aging, hypoglycemic, estrogenic activity and anti-ulcer properties. Ganoderma lucidum has now become recognized as an alternative adjuvant in the treatment of leukemia, carcinoma, hepatitis and diabetes. The macrofungus is very rare in nature rather not sufficient for commercial exploitation for vital therapeutic emergencies, therefore, the cultivation on solid substrates, stationary liquid medium or by submerged cultivation has become an essential aspect to meet the driving force towards the increasing demands in the international market. Present review focuses on the pharmacological aspects, cultivation methods and bioactive metabolites playing a significant role in various therapeutic applications.
    Current pharmaceutical biotechnology 12/2009; 10(8):717-42. DOI:10.2174/138920109789978757 · 2.51 Impact Factor